Diagnosis, misdiagnosis and management of hyperprolactinemia

References

• Franks S, Murray MA, Jequier AM, Steele SJ, Nabarro JD, Jacobs HS. Incidence and significance of hyperprolactinaemia in women with amenorrhea. Clin. Endocrinol. (Oxf.) 4, 597–607 (1975).
   PubMed Web of Science ®Google Scholar
• Moult PJ, Rees LH, Besser GM. Pulsatile gonadotrophin secretion in hyperprolactinemic amenorrhoea and the response to bromocriptine therapy. Clin. Endocrinol. (Oxf.) 16, 153–162 (1982).
   PubMed Web of Science ®Google Scholar
• Schlechte JA. Clinical practice. Prolactinoma. N. Engl J. Med. 349, 2035–2041 (2003).
   PubMed Web of Science ®Google Scholar
• Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary 5, 55–65 (2002).
   PubMedGoogle Scholar
• Vallette-Kasic S, Morange-Ramos I, Selim A et al. Macroprolactinemia revisited: a study on 106 patients. J. Clin. Endocrinol. Metab. 87, 581–588 (2002).
   PubMed Web of Science ®Google Scholar
• Schlechte JA. The macroprolactin problem. J. Clin. Endocrinol. Metab. 87, 5408–5409 (2002).
   PubMed Web of Science ®Google Scholar
• Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin. Endocrinol. (Oxf.) 62, 633–643 (2005).
   PubMed Web of Science ®Google Scholar
• Suliman AM, Smith TP, Gibney J, McKenna TJ. Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clin. Chem.49, 1504–1509 (2003).
   PubMed Web of Science ®Google Scholar
• Guay AT, Sabharwal P, Varma S, Malarkey WB. Delayed diagnosis of psychological erectile dysfunction because of the presence of macroprolactinemia. J. Clin. Endocrinol. Metab. 81, 2512–2514 (1996).
   PubMed Web of Science ®Google Scholar
• Suliman AM, Al-Saber F, Hayes F et al. Hyperprolactinaemia: analysis of presentation, diagnosis and treatment in the endocrine service of a general hospital. Ir. Med. J. 93, 74–76 (2000).
   PubMedGoogle Scholar
• Melmed S, Kleinberg D. Anterior Pituitary. In: Williams Textbook of Endocrinology. Williams R, Larsen P, Kronenburg H et al. (Eds). WB Saunders, CA, USA, 177–279 (2002).
   Google Scholar
• Thorner MO, Vance ML, Laws ER, Horvath E, Kovacs K. The anterior pituitary. In: Williams Textbook of Endocrinology. Wilson JD, Foster DW, Kronenburg HM, Reed Larsen P (Eds). WB Saunders Company, PA, USA, 249–340 (1998).
   Google Scholar
• Sam SM, Mark E. The pituitary mass: diagnosis and management. Rev. Endoc. Metab. Disord. 6, 55–62 (2005).
   PubMed Web of Science ®Google Scholar
• Rosato F, Garofalo P. Hyperprolactinemia: from diagnosis to treatment. Minerva Pediatr. 54, 547–552 (2002).
   PubMedGoogle Scholar
• Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi H. Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with antiprolactin autoantibody. Eur. J. Endocrinol. 130, 438–445 (1994).
   PubMed Web of Science ®Google Scholar
• Smith TP, McKenna TJ. Prevalence of macroprolactinaemia in various hyperprolactinemic states. Irish J. Med. Sci. 167, 6 (1998).
   Google Scholar
• Rogol AD, Rosen SW. Prolactin of apparent large molecular size: the major immunoactive prolactin component in plasma of a patient with a pituitary tumor. J. Clin. Endocrinol. Metab. 38, 714–717 (1974).
   PubMed Web of Science ®Google Scholar
• Whittaker PG, Wilcox T, Lind T. Maintained fertility in a patient with hyperprolactinemia due to big, big prolactin. J. Clin. Endocrinol. Metab. 53, 863–866 (1981).
   PubMed Web of Science ®Google Scholar
• Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi H. A normal ovulatory woman with hyperprolactinemia: presence of anti prolactin autoantibody and the regulation of prolactin secretion. Acta Endocrinol. (Copenh.)126, 497–500 (1992).
   PubMedGoogle Scholar
• Leite V, Cosby H, Sobrinho LG, Fresnoza MA, Santos MA, Friesen HG. Characterization of big, big prolactin in patients with hyperprolactinaemia. Clin. Endocrinol. (Oxf.) 37, 365–372 (1992).
   PubMed Web of Science ®Google Scholar
• Fahie-Wilson MN, Ellis AR. Macroprolactin; high molecular mass forms of circulating prolactin. Ann. Clin. Biochem. 42, 175–192 (2005).
   PubMed Web of Science ®Google Scholar
• Cavaco B, Leite V, Santos MA, Arranhado E, Sobrinho LG. Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. J. Clin. Endocrinol. Metab. 80, 2342–2346 (1995).
   PubMed Web of Science ®Google Scholar
• Hattori N, Ikekubo K, Nakaya Y, Kitagawa K, Inagaki C. Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to antiPRL autoantibodies. J. Clin. Endocrinol. Metab. 90, 3036–3044 (2005).
   PubMed Web of Science ®Google Scholar
• Pearson E, Paisley RB, Bower LM, Dearman GP, Fahie-Wilson MN, Alqhuist JAO. Macroprolactin in pregnancy, suckling and offspring. Endocrin. Abs. 1, 38 (2001).
   Google Scholar
• Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol. Rev. 80, 1523–1631 (2000).
   PubMed Web of Science ®Google Scholar
• Klibanski A. The effects of prolactin and oestrogen deficiency in amenorrhoic bone loss. J.Clin. Endocrinol. Metab. 67, 124–130 (1988).
   PubMed Web of Science ®Google Scholar
• Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin. Reprod. Med. 20, 365–374 (2002).
   PubMed Web of Science ®Google Scholar
• Fahie-Wilson M. In hyperprolactinemia, testing for macroprolactin is essential. Clin. Chem.49, 1434–1436 (2003).
   PubMed Web of Science ®Google Scholar
• Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi H. Effects of antiprolactin autoantibodies on serum prolactin measurements. Eur. J. Endocrinol. 130, 434–437 (1994).
   PubMed Web of Science ®Google Scholar
• Olukoga AO, Kane J. Screening for macroprolactinaemia. Ann. Clin. Biochem. 34, 701–703 (1997).
   PubMed Web of Science ®Google Scholar
• Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J. Clin. Endocrinol. Metab. 90, 3927–3932 (2005).
   PubMed Web of Science ®Google Scholar
• Fahie-Wilson MN. Polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin. Chem.45, 436–437 (1999).
   PubMed Web of Science ®Google Scholar
• Gilberto J, Vieira H, Tachibana TT, Obara LH, Maciel RM. Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin. Chem.44, 1758–1789 (1998).
   PubMed Web of Science ®Google Scholar
• Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J. Clin. Endocrinol. Metab. 87, 5410–5415 (2002).
   PubMed Web of Science ®Google Scholar
• Aron DC, Howlett TA. Pituitary incidentalomas. Endocrinol. Metab. Clin. North Am. 29, 205–221 (2000).
   PubMed Web of Science ®Google Scholar
• Molitch ME. Pathological hyperprolactinaemia. Endocrinol. Metab. Clin. North Am. 22, 877–901 (1992).
   Google Scholar
• Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin. Endocrinol. (Oxf.) 51, 119–126 (1999).
   PubMed Web of Science ®Google Scholar
• Molitch ME, Russell EJ. The pituitary ‘incidentaloma’. Ann. Intern. Med. 112, 925–931 (1990).
   PubMed Web of Science ®Google Scholar
• Webster J, Polli A et al. A comparison of cabergoline and bromocriptine n the treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. 331, 904–909 (1994).
   PubMed Web of Science ®Google Scholar
• Verhelst J, Maiter D et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab. 84, 2518–2522 (1999).
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N. Engl J. Med. 349, 2023–2033 (2003).
   PubMed Web of Science ®Google Scholar
• Molitch ME. Pregnancy and a hyperprolactinemic woman. N.Engl. J. Med. 312, 1364 (1985).
   PubMed Web of Science ®Google Scholar
• Prager D, Braunstein G. Pituitary disorders during pregnancy. Endo. Metab. Clin. N. Am. 24, 1–4 (1995).
   PubMed Web of Science ®Google Scholar
• Molitch ME, Elton RL, Blackwell RE et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab. 60, 698–705 (1985).
   PubMed Web of Science ®Google Scholar
• Biller BM, Molitch ME, Vance ML et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J. Clin. Endocrinol. Metab. 81, 2338–2343 (1996).
   PubMed Web of Science ®Google Scholar
• Fiad TM, McKenna TJ. Meningitis as a late complication of surgically and medically treated pituitary adenoma. Clin. Endocrinol. (Oxf.) 35, 419–422 (1991).
   PubMed Web of Science ®Google Scholar
• Olukoga AO, Dornan TL, Kane JW. Three cases of macroprolactinaemia. J. R. Soc. Med. 92, 342–344 (1999).
   PubMed Web of Science ®Google Scholar
• Cattaneo FA, Fahie-Wilson MN. Concomitant occurrence of macroprolactin, exercise-induced amenorrhea, and a pituitary lesion: a diagnostic pitfall. Case report. J. Neurosurg. 95, 334–337 (2001).
   PubMed Web of Science ®Google Scholar
• Klee G. College of American Pathologists; Special Ligands Participants Summary Report. 10 (2004).
   Google Scholar
• Sturgeon C, Ellis AR, Al-Sadie R, Logan M, Costa M. UK NEQAS for peptide hormones and related substances. Ann. Rev. 16–23 (2003).
   Google Scholar